Blackstone Life Sciences Invests $250M in Anagram Therapeutics

BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

May 16, 2025

Healthcare Services

BioMarin Pharmaceutical Inc. completed its all-cash acquisition of Inozyme Pharma, Inc. for $4.00 per share, valuing the deal at approximately $270 million. The transaction adds INZ-701, a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin’s enzyme therapies portfolio.

AlphaRose Therapeutics Acquires Alpha Anomeric SA

April 29, 2025

Biotechnology

AlphaRose Therapeutics has acquired Alpha Anomeric SA, a Paris-based developer of the abcDNA oligonucleotide chemistry platform. The acquisition brings a proprietary antisense oligonucleotide chemistry into AlphaRose's portfolio and establishes a European presence to support global development of its neurogenetic and rare-disease programs. Terms were not disclosed.

Ampersand Capital Partners Acquires Biologos LLC

March 19, 2024

Biotechnology

Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.

Ampersand Capital Partners Invests in AnaBios Corporation

June 7, 2022

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.

Blackstone Acquires Ancestry for $4.7 Billion

August 5, 2020

Media & Entertainment

Blackstone's private equity funds have entered a definitive agreement to acquire Ancestry from Silver Lake, GIC, Spectrum Equity, Permira and other equity holders for an enterprise value of $4.7 billion; GIC will retain a significant minority stake. Blackstone said it will partner with Ancestry's management to invest in data, product development and global expansion of the company's family history and consumer genomics platform, which has more than 3 million paying subscribers and roughly $1 billion in annual revenue.